Clinical Trials · NCT03422666
Plasma Lipoprotein Response to Glucagon-like Peptide-2
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- University Health Network, Toronto
- Enrollment
- 10
- Start date
- Sep 2018
- Locations
- 1 site, Canada
- Primary endpoint
- Lipoprotein response to teduglutide